This Week in Startups · September 4, 2026 · 58m

Dr. Mark Hyman on Function Health & GLP-1 microdosing | E2334

Dr. Mark Hyman joins Jason to discuss Function Health, his platform that aggregates 100+ biomarkers to catch disease early. They explore why standard lab ranges are unreliable, why insulin is a better early warning than blood sugar, and the staggering statistic that 93% of Americans show signs of metabolic dysfunction. The conversation covers GLP-1 medications, including Jason's personal weight loss story and the emerging practice of microdosing to avoid muscle loss. They also discuss the biology underlying depression and anxiety, the potential of psychedelics like ibogaine for PTSD, and how AI might transform diagnostic medicine.

This summary was generated from show notes and public descriptions, not from a full transcript review. Details may contain inaccuracies.

Preview

•

Function Health Is Fixing a Broken Diagnostic System00:00

Dr. Hyman describes Function Health as a platform that aggregates over 100 biomarkers to detect disease early, targeting a healthcare system he calls 'sick care' rather than true healthcare.

Claude ChatGPT Gemini

•

93% of Americans Have Metabolic Dysfunction34:31

Citing a Tufts / JACC study, Dr. Hyman states that only 7% of American adults have good cardiometabolic health, meaning 93% show some degree of metabolic dysfunction.

Claude ChatGPT Gemini

4 more ideas & all timestamps

This episode is in its early-access window. The full breakdown unlocks free in about 71 hours — Pro members read everything the moment it lands.

Read it now with Pro$10/mo · founding $96/yr

Was this useful?